No Contraindications to Combined Use
There are no contraindications to using rosuvastatin and Vascepa (icosapent ethyl) together. In fact, this combination is specifically supported by clinical evidence and represents a guideline-recommended approach for cardiovascular risk reduction in appropriate patients.
Evidence Supporting Combined Use
The FDA-approved labeling for both medications lists only specific contraindications that do not include each other:
- Vascepa contraindications: Only hypersensitivity to the drug or its components 1
- Rosuvastatin contraindications: Acute liver failure/decompensated cirrhosis and hypersensitivity reactions 2
Clinical Evidence for Combination Therapy
The landmark REDUCE-IT trial specifically evaluated icosapent ethyl added to statin therapy (including rosuvastatin) in patients with elevated triglycerides. This combination demonstrated:
- Significant reduction in cardiovascular events 3
- Fewer total hospitalizations and days lost to hospitalization/death 3
- Benefit in statin-treated patients with triglycerides 1.69-5.63 mmol/L and controlled LDL-C 4, 5
Current guidelines explicitly endorse this combination for patients on maximally tolerated statin therapy who have residual cardiovascular risk with elevated triglycerides 4, 5.
Safety Profile of the Combination
Research specifically examining rosuvastatin drug interactions confirms that combination treatment with omega-3 fatty acids (including icosapent ethyl) is safe, with no evidence of pharmacokinetic or pharmacodynamic interactions 6. Rosuvastatin's minimal cytochrome P450 metabolism and high hepatoselectivity contribute to its favorable interaction profile 6.
Clinical Application
This combination is appropriate for patients who:
- Are on maximally tolerated statin therapy (including rosuvastatin)
- Have established ASCVD or diabetes with additional risk factors
- Have persistently elevated triglycerides (135-499 mg/dL in REDUCE-IT)
- Have controlled LDL-C levels
The combination addresses residual cardiovascular risk through complementary mechanisms without safety concerns.